NDC 82982-031 Benzonatate
What is NDC 82982-031?
The NDC code 82982-031 is assigned by the FDA to the product Benzonatate which is a human prescription drug product labeled by Pharmasource Meds, Llc. The product's dosage form is capsule and is administered via oral form. The product is distributed in a single package with assigned NDC code 82982-031-30 30 capsule in 1 bottle . This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information, RxNorm crosswalk and the complete product label.
What are the uses for Benzonatate?
This medication is used to treat coughs caused by the common cold and other breathing problems (e.g., pneumonia, bronchitis, emphysema, asthma). It works by reducing the reflex in the lungs that causes the urge to cough. Use of this medication is not recommended in children younger than 10 years. Discuss the risks and benefits with your doctor.
|Color(s)||YELLOW (C48330) |
|Shape||OVAL (C48345) |
|Size(s)||9 MM |
NDC Code 82982-031-30
Package Description: 30 CAPSULE in 1 BOTTLE
What are Benzonatate Active Ingredients?
Benzonatate Active Ingredients UNII Codes
- BENZONATATE (UNII: 5P4DHS6ENR)
- BENZONATATE (UNII: 5P4DHS6ENR) (Active Moiety)
Benzonatate Inactive Ingredients UNII Codes
- D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)
- GELATIN (UNII: 2G86QN327L)
- GLYCERIN (UNII: PDC6A3C0OX)
- LECITHIN, SOYBEAN (UNII: 1DI56QDM62)
- LIGHT MINERAL OIL (UNII: N6K5787QVP)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- SHELLAC (UNII: 46N107B71O)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- WATER (UNII: 059QF0KO0R)
* Please review the disclaimer below.
Benzonatate Product Label
FDA filings in the form of structured product labels are documents that include all published material associated whith this product. Product label information includes data like indications and usage generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.
Product Label Table of Contents
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- PSYCHIATRIC EFFECTS
- ACCIDENTAL INGESTION AND DEATH IN CHILDREN
- INFORMATION FOR PATIENTS:
- USAGE IN PREGNANCY
- NURSING MOTHERS
- CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY
- PEDIATRIC USE
- ADVERSE REACTIONS
- HYPERSENSITIVITY REACTIONS
- SIGNS AND SYMPTOMS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 200 MG 30CT
Benzonatate capsules, USP, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26- onaoxaoctacosan-28-ylp-(butylamino) benzoate; with a molecular weight of 603.7. Each benzonatate capsules, USP for oral administration contains 100 mg or 200 mg benzonatate, USP. In addition, each capsule contains the following inactive ingredients: D&C Yellow #10, gelatin, glycerin, lecithin, light mineral oil, propylene glycol, purified water, shellac glaze, titanium dioxide, and white edible ink.
Benzonatate capsules act peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate capsules have no inhibitory effect on the respiratory center in recommended dosage.
Indications And Usage
Benzonatate capsules, USP are indicated for the symptomatic relief of cough.
Hypersensitivity to benzonatate or related compounds.
Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.
Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking Benzonatate capsules in combination with other prescribed drugs.
Accidental Ingestion And Death In Children
Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate capsules resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE).
Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.
Information For Patients:
Swallow benzonatate capsules whole. Do not break, chew, dissolve, cut, or crush benzonatate capsules. Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of food or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.
Keep benzonatate capsules out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately.
Overdosage resulting in death may occur in adults.
Do not exceed a single dose of 200 mg and a total daily dosage of 600 mg. If you miss a dose of benzonatate capsules, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of benzonatate capsules at one time.
Usage In Pregnancy
PREGNANCY CATEGORY C
Animal reproduction studies have not been conducted with benzonatate capsules. It is also not known whether benzonatate capsules can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate capsules should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when benzonatate capsules are administered to a nursing woman.
Carcinogenesis, Mutagenesis, Impairment Of Fertility
Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate capsules..
Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.
Potential Adverse Reactions to benzonatate capsules may include:
Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.
sedation; headache; dizziness; mental confusion; visual hallucinations.
constipation; nausea; GI upset.
pruritus; skin eruptions.
nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity.
Deliberate or accidental overdose has resulted in death, particularly in children.
including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.
Intentional and unintentional overdose may result in death, particularly in children.
The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.
Signs And Symptoms
The signs and symptoms of overdose of benzonatate capsules have been reported within 15-20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise.
CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.
In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.
Do not use CNS stimulants.
Dosage And Administration
Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate capsules should be swallowed whole. Benzonatate capsules are not to be broken, chewed, dissolved, cut or crushed.
Benzonatate Capsules USP, 200 mg are clear yellow, oval-shaped softgel capsules imprinted with “PC15” and are supplied as follows:
NDC 82982-031-30 in bottle of 30 capsules
Store at 20˚ to 25˚ C (68˚ to 77˚ F) [see USP Controlled Room Temperature].
PROTECT FROM LIGHT
Dispense in tight (USP), child-resistant containers.
Humanwell PuraCap Pharmaceutical
Wuhan, Hubei 430206, China
Epic Pharma, LLC
Laurelton, NY 11413
Pharmasource Meds, LLC
Tigard OR 97223
Package/Label Principal Display Panel – 200 Mg 30Ct
Benzonatate 200 mg
Pharmasource Meds, LLC
* Please review the disclaimer below.